Clinical Trial Design and Objectives

This study is a Phase 1 safety and feasibility trial that commenced on July 29, 2020, enrolling infants with congenital heart disease who undergo biventricular surgery within the first six months of life. It is a single‑center, open‑label trial evaluating the administration of allogeneic bone marrow‑derived mesenchymal stem cells (BM‑MSC) during cardiopulmonary bypass (CPB). Enrollment has now closed, and ongoing data will be pivotal for safety assessment.

Target Disease and Current Standard of Care

Congenital heart disease (CHD) is one of the most common birth defects in neonates, and surgery remains the primary treatment. Post‑operative tissue injury and delayed recovery remain significant challenges. Existing therapies include pharmacologic and mechanical support, but regenerative treatment options are limited.

Mechanism of Action and Anticipated Benefits of MSCs

Mesenchymal stem cells (MSCs) possess anti‑inflammatory, immunomodulatory, and regenerative properties that may minimize tissue injury and accelerate healing. Bone‑marrow‑derived cells are relatively abundant, and allogeneic transplantation carries a low risk of immune rejection, facilitating clinical use. This study is the first to evaluate whether these mechanisms operate effectively in the infant surgical setting.

Industry and Research Impact

If safety and early efficacy are demonstrated, development of cell‑based therapies for pediatric cardiac surgery could accelerate. This could represent an initial shift from surgery‑centric treatment toward a regenerative‑medicine paradigm. Moreover, expansion into multi‑center, multi‑phase trials would create new market opportunities for investors and biopharma companies.